Cardiovascular and cerebrovascular safety of vildagliptin, a potent inhibitor of the dipeptidyl peptidase type 4 for the treatment of type 2 diabetes

被引：0
|
作者：
Dejager, S. [1 ]
Meen, S. [2 ]
Reigneau, O. [1 ]
Kothny, W. [3 ]
机构：
[1] Novartis Pharmaceut, Rech Clin, Rueil Malmaison, France
[2] Lab Novartis Pharma Sas, Rueil Malmaison, France
[3] Novartis, Rech Clin, E Hanover, NJ USA
来源：
DIABETES & METABOLISM | 2009年 / 35卷
关键词：
D O I：
10.1016/S1262-3636(09)71922-6
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A57 / A57
页数：1
相关论文
共 50 条
  • [1] Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes
    Stein, Stephanie A.
    Lamos, Elizabeth M.
    Davis, Stephen N.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2014, 10 (04) : 599 - 608
  • [2] Vildagliptin - A dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes
    Schlesselman, Lauren S.
    FORMULARY, 2006, 41 (10) : 494 - +
  • [3] Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes
    Del Prato, S.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 : 38 - 48
  • [4] Safety of Dipeptidyl Peptidase 4 Inhibitors for Treatment of Type 2 Diabetes
    Mikhail, Nasser
    CURRENT DRUG SAFETY, 2011, 6 (05) : 304 - 309
  • [5] Vildagliptin.: Agent for type 2 diabetes, dipeptidyl-peptidase IV inhibitor
    McIntyre, JA
    Castañer, J
    DRUGS OF THE FUTURE, 2004, 29 (09) : 887 - 891
  • [6] Comparative Effectiveness of Dipeptidyl Peptidase-4 Inhibitor for the Risk of Cardiovascular and Cerebrovascular Disease in Patients with Type 2 Diabetes
    Seong, Jong-Mi
    Choi, Nam-Kyong
    Shin, Ju-Young
    Kim, Ye-Jee
    Lee, Joongyub
    Park, Byung-Joo
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 237 - 237
  • [7] Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
    Tiwari, Atul
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (10) : 1091 - 1104
  • [8] The Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus: Cardiovascular Safety
    Green, Jennifer B.
    POSTGRADUATE MEDICINE, 2012, 124 (04) : 54 - 61
  • [9] Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes
    Deacon, Carolyn F.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2008, 9 (04) : 402 - 413
  • [10] Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes
    Azuma, Koichiro
    Radikova, Zofia
    Mancino, Juliet
    Toledo, Frederico G. S.
    Thomas, Ernestine
    Kangani, Cyrous
    Man, Chiara Dalla
    Cobelli, Claudio
    Holst, Jens J.
    Deacon, Carolyn F.
    He, YanLing
    Ligueros-Saylan, Monica
    Serra, Denise
    Foley, James E.
    Kelley, David E.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (02): : 459 - 464
12345